Non-coding Sequences Having No Known Regulatory Function Which Are Adaptors Or Linkers For Vector Or Gene Contruction Patents (Class 536/24.2)
-
Patent number: 8487084Abstract: In some embodiments, DNA-capped nanoparticles are used to define a degree of crystalline order in assemblies thereof. In some embodiments, thermodynamically reversible and stable body-centered cubic (bcc) structures, with particles occupying <˜10% of the unit cell, are formed. Designs and pathways amenable to the crystallization of particle assemblies are identified. In some embodiments, a plasmonic crystal is provided. In some aspects, a method for controlling the properties of particle assemblages is provided. In some embodiments a catalyst is formed from nanoparticles linked by nucleic acid sequences and forming an open crystal structure with catalytically active agents attached to the crystal on its surface or in interstices.Type: GrantFiled: April 3, 2009Date of Patent: July 16, 2013Assignee: Brookhaven Science Associates, LLCInventors: Oleg Gang, Dmytro Nykypanchuk, Mathew Maye, Daniel van der Lelie
-
Patent number: 8481257Abstract: The invention relates to a method for the high throughput discovery, detection and genotyping of one or more genetic markers in one or more samples, comprising the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries and determination of (co-) dominant genotypes of the genetic markers.Type: GrantFiled: December 20, 2006Date of Patent: July 9, 2013Assignee: Keygene N.V.Inventors: Michael Josephus Theresia Van Eijk, Anker Preben Sørensen, Marco Gerardus Maria Van Schriek
-
Publication number: 20130164757Abstract: There is provided a method for producing a circular DNA which consists of a circular DNA formed from a single-molecule DNA and which does not comprise circular DNA formed from multiple-molecule DNA. According to the method of the present invention, a circular DNA molecule formed only from a single-molecule DNA can be reliably produced.Type: ApplicationFiled: August 22, 2011Publication date: June 27, 2013Inventors: Shinichi Mizuno, Koji Nagafuji, Takashi Okamura
-
Publication number: 20130133113Abstract: The present invention relates to nucleic acid molecules corresponding to regulatory portions of genes whose expression is constitutive. The invention also relates to compositions and methods of using the same to regulate the expression, in a constitutive manner, of genes and/or any kind of nucleotide sequences in a plant. Nucleic acid molecules and its compositions include novel nucleotide sequences for constitutive promoter identified in and isolated from poplar (Populus spp). Methods for expressing genes and/or any kind of nucleotide sequences in a plant using the promoter sequences disclosed herein are provided. The methods comprise stably incorporating into the genome of a plant cell a nucleotide sequence operably linked to one or more of the constitutive promoters of the present invention and regenerating a stably transformed plant that expresses the nucleotide sequence.Type: ApplicationFiled: December 13, 2012Publication date: May 23, 2013Applicant: Alellyx S.A.Inventor: Alellyx S.A.
-
Patent number: 8445196Abstract: Random arrays of single molecules are provided for carrying out large scale analyses, particularly of biomolecules, such as genomic DNA, cDNAs, proteins, and the like. In one aspect, arrays of the invention comprise concatemers of DNA fragments that are randomly disposed on a regular array of discrete spaced apart regions, such that substantially all such regions contain no more than a single concatemer. Preferably, such regions have areas substantially less than 1 ?m2 and have nearest neighbor distances that permit optical resolution of on the order of 109 single molecules per cm2. Many analytical chemistries can be applied to random arrays of the invention, including sequencing by hybridization chemistries, sequencing by synthesis chemistries, SNP detection chemistries, and the like, to greatly expand the scale and potential applications of such techniques.Type: GrantFiled: October 31, 2007Date of Patent: May 21, 2013Assignee: Callida Genomics, Inc.Inventors: Radoje T. Drmanac, Matthew J. Callow, Snezana Drmanac, Brian K. Hauser, George Yeung
-
Patent number: 8445254Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Type: GrantFiled: November 10, 2009Date of Patent: May 21, 2013Assignees: The Arizona Board of Regents for and on Behalf of Arizona State University, The Washington UniversityInventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
-
Patent number: 8445197Abstract: Random arrays of single molecules are provided for carrying out large scale analyses, particularly of biomolecules, such as genomic DNA, cDNAs, proteins, and the like. In one aspect, arrays of the invention comprise concatemers of DNA fragments that are randomly disposed on a regular array of discrete spaced apart regions, such that substantially all such regions contain no more than a single concatemer. Preferably, such regions have areas substantially less than 1 ?m2 and have nearest neighbor distances that permit optical resolution of on the order of 109 single molecules per cm2. Many analytical chemistries can be applied to random arrays of the invention, including sequencing by hybridization chemistries, sequencing by synthesis chemistries, SNP detection chemistries, and the like, to greatly expand the scale and potential applications of such techniques.Type: GrantFiled: October 31, 2007Date of Patent: May 21, 2013Assignee: Callida Genomics, Inc.Inventors: Radoje Drmanac, Matthew J. Callow, Snezana Drmanac, Brian K. Hauser, George Yeung
-
Patent number: 8435783Abstract: The invention provides engineered plant minichromosomes generated by telomere mediated truncation of native chromosomes. These minichromosomes are faithfully transmitted from one generation to the next and provide an ideal platform for breeding genes into desired plant varieties with out problems, such as linkage drag, associated with standard breeding methods.Type: GrantFiled: August 9, 2011Date of Patent: May 7, 2013Assignee: The Curators of the University of MissouriInventors: Weichang Yu, Juan M. Vega, James Birchler
-
Patent number: 8420388Abstract: The present invention provides a porcine beta-casein gene, a porcine beta-casein gene promoter, an expression vector comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates mammary gland-specific expression of the target protein and therefore can be useful for high-concentration production of beneficial proteins in milk.Type: GrantFiled: December 31, 2008Date of Patent: April 16, 2013Assignee: Cho-A Pharm. Co., Ltd.Inventors: Jin Hoi Kim, Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn
-
Patent number: 8420075Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.Type: GrantFiled: March 30, 2010Date of Patent: April 16, 2013Assignee: Biovec, LLCInventors: Lakshman R. Sehgal, Jonathan Wong
-
Patent number: 8399637Abstract: This invention relates to an isolated protein MONaKA and methods of its use. Specifically, the invention is directed to a protein that modulates the Na,K-ATPase and glutamate transporters, by binding to the b-subunit of the plasma membrane Na,K-ATPase (Na pump).Type: GrantFiled: August 24, 2007Date of Patent: March 19, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: Tanya S. Ferguson, Irwin Levitan, Susan M. Cibulsky
-
Publication number: 20130059342Abstract: The present invention relates to compositions and methods for use in recombinational cloning of nucleic acid molecules. In particular, the invention relates to nucleic acid molecules encoding one or more recombination sites or portions thereof, to nucleic acid molecules comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more additional physical or functional nucleotide sequences. The invention also relates to vectors comprising nucleic acid molecules of the invention, to host cells comprising vectors or nucleic acid molecules of the invention, to methods of producing polypeptides using nucleic acid molecules of the invention, and to polypeptides encoded by these nucleic acid molecules or produced by methods of the invention. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments.Type: ApplicationFiled: June 28, 2012Publication date: March 7, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: James L. HARTLEY, Michael A. Brasch, Gary F. Temple, David Cheo
-
Patent number: 8389707Abstract: Oligonucleotide structures are provided that are capable of forming more stable bonds to a lipid membrane and thereby generate an improved control of the process whereby oligonucleotide linkers are introduced to lipid membranes. Methods of forming lipid membrane oligonucleotide attachments are provided including lipid vesicles. The oligonucleotides typically comprise at least two hydrophobic anchoring moieties capable of being attached to a lipid membrane. Said moieties may be attached at the terminal ends of an oligonucleotide or, in the case of a first and second strand forming a duplex, at the same terminal end one of the strands other end not being part of the duplex leaving it free to hybridize to additional strands. The lipid vesicles attached with the oligonucleotide can be used in biosensors and may contain membrane proteins.Type: GrantFiled: February 28, 2005Date of Patent: March 5, 2013Assignee: Bio-Rad Laboratories Inc.Inventors: Indriati Pfeiffer, Fredrick Höök
-
Patent number: 8389238Abstract: Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3?BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3? BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.Type: GrantFiled: September 12, 2008Date of Patent: March 5, 2013Assignee: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Linas Padegimas
-
Patent number: 8383344Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: GrantFiled: June 1, 2009Date of Patent: February 26, 2013Assignee: Exiqon A/SInventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
-
Patent number: 8372966Abstract: The present invention describes reagents and methods for using a concatemerized double-stranded oligonucleotide molecules (CODN) for transcription factor decoys. In one embodiment, the concatemers consist of a variable number of end-to-end repeated copies of a short (more than 5, 10, 15, 20, 2, 3035, 40, 45, 50, 75, 100, or more by but generally less than about 3 kb) dsDNA containing a sequence or sequences that act as transcription factor decoys. The present invention also provides for the use of the polymers for CODN/polymer complexes to a specific cell type; thus the agent can be made organ, tissue and/or cell-type specific. In another embodiment, the present invention provides for use of the CODN's in vitro or in vivo, in isolated cells or intact animals in which specific blockade of transcription factors or delivery of DNA or other biological effector is desirable.Type: GrantFiled: December 20, 2004Date of Patent: February 12, 2013Assignee: University of CincinnatiInventor: Walter Keith Jones
-
Patent number: 8362229Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes.Type: GrantFiled: February 8, 2007Date of Patent: January 29, 2013Assignee: Quark Pharmaceuticals, Inc.Inventors: Huseyin Aygun, Elena Feinstein
-
Publication number: 20130023009Abstract: Provided is a method for selectively obtaining, for a given target gene, a “joined DNA fragment” wherein just a target gene fragment is joined with desired other DNA fragments, regardless of whether a DNA fragment containing a target gene sequence has been purified. In the provided method, a double-stranded joining DNA fragment containing a sequence A and/or a sequence B is selectively joined to the ends of a target gene fragment. A mixture of a double-stranded gene fragment, the 3? end of which is protruding, and the double-stranded joining DNA fragment, which are related in a prescribed manner, undergoes at least two cycles of thermal denaturation, reassociation, and DNA synthesis, resulting in a “joined DNA fragment,” which is a double-stranded DNA fragment including at least one instance of a sequence resulting from joining sequence A, the target gene sequence, and sequence B. A “single-side joined DNA fragment” can also be obtained, by a similar method.Type: ApplicationFiled: September 2, 2010Publication date: January 24, 2013Applicant: NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Nobuyuki Kurosawa, Masaharu Isobe
-
Patent number: 8357789Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.Type: GrantFiled: September 18, 2009Date of Patent: January 22, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
-
Patent number: 8344131Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.Type: GrantFiled: January 23, 2012Date of Patent: January 1, 2013Assignee: Novartis AGInventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
-
Patent number: 8344129Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.Type: GrantFiled: January 23, 2012Date of Patent: January 1, 2013Assignee: Novartis AGInventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
-
Patent number: 8344130Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.Type: GrantFiled: January 23, 2012Date of Patent: January 1, 2013Assignee: Novartis AGInventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
-
Patent number: 8344127Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.Type: GrantFiled: April 20, 2011Date of Patent: January 1, 2013Assignee: Novartis AGInventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Sprague
-
Patent number: 8338091Abstract: The present invention is in the fields of biotechnology and molecular biology. More particularly, the present invention relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites. The present invention also embodies cloning such nucleic acid molecules using recombinational cloning methods such as those employing recombination sites and recombination proteins. The present invention also relates to nucleic acid molecules (including RNA and iRNA), as well as proteins, expressed from host cells produced using the methods of the present invention.Type: GrantFiled: February 21, 2012Date of Patent: December 25, 2012Assignee: Life Technologies CorporationInventors: Jonathan Chesnut, Miroslav Dudas, Adam Harris, Louis Leong, Knut Madden
-
Publication number: 20120324603Abstract: The invention relates to chimeric endonucleases, comprising an endonuclease and a heterologous DNA binding domain, as well as methods of targeted integration, targeted deletion or targeted mutation of polynucleotides using chimeric endonucleases.Type: ApplicationFiled: November 26, 2010Publication date: December 20, 2012Applicant: BASF Plant Sceience Company GmbHInventors: Andrea Hlubek, Christian Biesgen, Hans Wolfgang Höffken
-
Patent number: 8329887Abstract: The present invention relates generally to methods, compositions and kits for synthesizing sense RNA molecules from one or more RNA molecules of interest in a sample. In exemplary embodiments, the methods use a terminal tagging oligoribonucleotide (rTTO) to join a DNA sequence tag to the 3?-termini of first-strand cDNA molecules. The use of an rTTO comprising ribonucleotides results in decreased oligonucleotide-derived background synthesis of RNA in the absence of sample RNA and, surprisingly and unexpectedly, also results in significantly increased yields of sense RNA molecules that exhibit sequences that are substantially identical to those of the RNA molecules of interest in the sample. The sense RNA molecules also have an RNA sequence tag on their 5?-termini that is useful for fixing the lengths of sense RNA molecules that are synthesized in a second or subsequent round.Type: GrantFiled: September 20, 2011Date of Patent: December 11, 2012Assignee: Cellscript, Inc.Inventors: Gary Dahl, Roy Rabindranauth Sooknanan
-
Patent number: 8318493Abstract: Methods and compositions using populations of randomized modified FRT recombination sites to identify, isolate and/or characterize modified FRT recombination sites are provided. The recombinogenic modified FRT recombination sites can be employed in a variety of methods for targeted recombination of polynucleotides of interest, including methods to recombine polynucleotides, assess promoter activity, directly select transformed organisms, minimize or eliminate expression resulting from random integration into the genome of an organism, such as a plant, remove polynucleotides of interest, combine multiple transfer cassettes, invert or excise a polynucleotide, and identify and/or characterize transcriptional regulating regions are also provided.Type: GrantFiled: April 8, 2010Date of Patent: November 27, 2012Assignee: Pioneer Hi-Bred International, Inc.Inventors: Yumin Tao, Dennis L. Bidney, William J. Gordon-Kamm, Leszek A. Lyznik
-
Patent number: 8314223Abstract: The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.Type: GrantFiled: January 18, 2009Date of Patent: November 20, 2012Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Patent number: 8304183Abstract: Methods are provided for adding a terminal sequence tag to nucleic acid molecules for use in RNA or DNA amplification. The tag introduced may be used as a primer binding site for subsequent amplification of the DNA molecule and/or sequencing of the DNA molecule and therefore provides means for identification and cloning of the 5?-end or the complete sequence of mRNAs.Type: GrantFiled: November 30, 2005Date of Patent: November 6, 2012Assignee: Cellscript, Inc.Inventor: Roy R. Sooknanan
-
Patent number: 8304233Abstract: The subject invention provides a unidirectional site-specific integration system for integrating a nucleic acid into the genome of a target cell. The provided system includes a site-specific integrating expression cassette (INTEC) vector, consisting of (a) a polynucleotide of interest operably linked to a promoter, (b) a single recombination site, and (c) a hybrid recombination site. In using the subject systems for site-specific integration, the INTEC vector and integrase are introduced into the target cell and the cell is maintained under conditions sufficient to provide for site-specific integration of the nucleic acid into the target cell genome via a recombination event mediated by the site-specific recombinase. Also provided are kits that include the subject systems. The subjects systems, methods and kits find use in a variety of different applications, several representative ones of which are described in detail as well.Type: GrantFiled: August 4, 2005Date of Patent: November 6, 2012Assignees: Poetic Genetics, LLC, The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Patent number: 8298767Abstract: Aspects of the present invention are drawn to processes for moving a region of interest in a polynucleotide from a first position to a second position with regard to a domain within the polynucleotide, also referred to as a “reflex method”. In certain embodiments, the reflex method results in moving a region of interest into functional proximity to specific domain elements present in the polynucleotide (e.g., primer sites and/or MID). Compositions, kits and systems that find use in carrying out the reflex processes described herein are also provided.Type: GrantFiled: August 13, 2010Date of Patent: October 30, 2012Assignee: Population Genetics Technologies LtdInventors: Sydney Brenner, Gi Mikawa, Robert Osborne, Andrew Slatter
-
Patent number: 8298819Abstract: The present invention aims to provide novel vectors for plant transformation. The vectors of the present invention are cosmid vectors having a full length of 15 kb or less characterized in that: 1) they contain an origin of replication of an IncP plasmid, but do not contain any origin of replication of other plasmid groups; 2) they contain the trfA1 gene of an IncP plasmid; 3) they contain an oriT of an IncP plasmid; 4) they contain the incC1 gene of an IncP plasmid; 5) they contain a cos site of lambda phage and the cos site is located outside the T-DNA; 6) they contain a drug resistance gene expressed in E.Type: GrantFiled: June 25, 2007Date of Patent: October 30, 2012Assignee: Japan Tobacco Inc.Inventors: Yoshimitsu Takakura, Toshihiko Komari, Yuji Ishida, Toshiyuki Komori, Yukoh Hiei, Toshiki Mine, Teruyuki Imayama
-
Patent number: 8278427Abstract: An assigning molecule obtained by ligating a genotype molecule to a phenotype molecule by transpeptidation, wherein the genotype molecule is constructed by bonding (a) a spacer molecule comprising a donor region which can be bonded to a 3?-terminal end of nucleic acid, a PEG region bonded to the donor region and a peptide acceptor region which is bonded to the PEG region, to (b) a 3? end of a nucleic acid comprising a 5? untranslated region comprising a transcription promoter and a translation enhancer; an ORF region which comprises a polyA sequence and which is bonded to the 3?-terminal side of the 5? untranslated region; and a 3?-terminal region that is bonded to the 3?-terminal side of the ORF region.Type: GrantFiled: June 13, 2003Date of Patent: October 2, 2012Assignee: KEIO UniversityInventors: Hiroshi Yanagawa, Etsuko Miyamoto, Hideaki Takashima
-
Patent number: 8268798Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.Type: GrantFiled: June 1, 2011Date of Patent: September 18, 2012Assignee: Alcon Research, Ltd.Inventor: Jon E. Chatterton
-
Patent number: 8252916Abstract: The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The invention relates to epitope cluster regions and to vectors including epitope cluster regions. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.Type: GrantFiled: April 30, 2004Date of Patent: August 28, 2012Assignee: MannKind CorporationInventors: John J. L. Simard, David C. Diamond, Zhiyong Qiu, Xiang-Dong Lei
-
Patent number: 8236558Abstract: BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.Type: GrantFiled: August 30, 2010Date of Patent: August 7, 2012Assignee: Novartis AGInventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
-
Patent number: 8227432Abstract: The present invention is directed to improved transposons and transposases. The present invention also includes gene transfer systems, methods of using the transposons and transposases, and compositions including the transposons and transposases.Type: GrantFiled: April 22, 2003Date of Patent: July 24, 2012Assignee: Regents of the University of MinnesotaInventors: Perry B. Hackett, Karl J. Clark, Zongbin Cui, Adam J. Dupuy, Aron M. Geurts, Geyi Liu
-
Patent number: 8202691Abstract: The invention provides a method for preparing and analysing a population of fragmented polynucleotide sequences having a substantially uniform size. The method can include steps of (a) binding at least one protection molecule to at least one polynucleotide sequence; (b) cleaving the at least one polynucleotide sequence to generate a plurality of polynucleotide fragment sequences of substantially uniform size; (c) amplifying the polynucleotide fragments; and (d) determining a sequence characteristic of a plurality of the polynucleotide fragments.Type: GrantFiled: January 22, 2009Date of Patent: June 19, 2012Assignee: Illumina, Inc.Inventors: Frank Steemers, Jonathan Mark Boutell
-
Patent number: 8192937Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: GrantFiled: April 7, 2005Date of Patent: June 5, 2012Assignee: Exiqon A/SInventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
-
Patent number: 8188254Abstract: The invention relates to a class of CpG immunostimulatory oligonucleotides containing a CpG immunostimulatory motif and a second motif which is capable of forming secondary structure, including duplex and higher order structures, in vitro and in vivo. The oligonucleotides of the invention are useful as adjuvants in vaccination. The oligonucleotides are also useful for inducing an immune response, inducing expression of a type I interferon (IFN), inducing expression of gamma interferon (IFN-?), and for treating a variety of conditions, including allergy, asthma, infection, and cancer.Type: GrantFiled: October 29, 2004Date of Patent: May 29, 2012Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg, Bernhard O. Noll
-
Patent number: 8183432Abstract: By inhibiting the function of a transcription factor that promotes transcription of a gene associated with the amounts of lignin and cellulose, a plant in which the amounts of lignin and cellulose are reduced without reducing the amount of glucan is produced. In this plant, glucan in the obtained cell wall components is in the state of highly easily undergoing saccharification. In this plant, moreover, natural dehiscence of pods is suppressed. A method of inhibiting the transcription factor includes a method in which a chimeric gene between a transcription factor gene and a polynucleotide that encodes a functional peptide capable of converting the transcription factor into a transcription repressor is introduced into a plant cell so that a chimeric protein in which the transcription factor is fused with the functional peptide is produced in a plant cell, and a method of inhibiting the expression of the transcription factor, such as knockout method or RNAi method.Type: GrantFiled: February 27, 2007Date of Patent: May 22, 2012Assignees: Japan Science and Technology Agency, National Institute of Advanced Industrial Science and TechnologyInventors: Masaru Takagi, Nobutaka Mitsuda, Akira Iwase, Keiichiro Hiratsu
-
Publication number: 20120108440Abstract: Provided herein is a method of reducing adapter dimer formation comprising contacting a sample comprising target nucleic acid sequences with 5? and 3? adapters in the presence of one or more hairpin oligonucleotides. Also provided is a method of preparing a library of nucleic acid sequences comprising contacting first adapter oligonucleotides with a sample comprising target nucleic acid sequences under conditions to form first ligation products, contacting the sample with one or more hairpin oligonucleotides that binds to the first adapter oligonucleotides, and contacting the sample with second adapter oligonucleotides under conditions to bind to the first ligation products and form second ligation products, wherein the second ligation products form the library of nucleic acid sequences.Type: ApplicationFiled: November 23, 2010Publication date: May 3, 2012Applicant: ILLUMINA, INC.Inventors: Patrick Lau, Danny Lee
-
Patent number: 8158768Abstract: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.Type: GrantFiled: September 24, 2009Date of Patent: April 17, 2012Assignee: Dynavax Technologies CorporationInventors: Dino Dina, Karen L. Fearon, Jason Marshall
-
Patent number: 8153420Abstract: Compositions having polynucleotides encoding multiple translational stop signals in more than one reading frame are provided. The compositions include isolated polynucleotides, expression cassettes, and vectors, as well as host cells, prokaryotic organisms, and eukaryotic organisms comprising the polynucleotide(s). Methods include using the polynucleotides to stop translation of an mRNA into a protein, to produce a transformed cell and/or organism comprising the polynucleotide, and to identify transformed cells or organisms of a specific lineage.Type: GrantFiled: July 31, 2008Date of Patent: April 10, 2012Assignee: Pioneer Hi Bred International IncInventors: Kimberly E Glassman, Shane E Abbitt, Karri Klein
-
Publication number: 20120083017Abstract: The present invention provides methods and compositions for asymmetrically tagging a nucleic acid fragment using asymmetric adapters.Type: ApplicationFiled: September 1, 2011Publication date: April 5, 2012Inventor: Gi Mikawa
-
Publication number: 20120040865Abstract: The present invention relates to a method and kit of detecting a target material using an aptamer, and more particularly to a method and kit for detecting a target material, in which a sample and a second aptamer are added to a first aptamer immobilized on a solid phase so as to form a bond sandwiched between the first aptamer, the target material and the second aptamer, to an FET sensor-based method and kit for detecting a target material, and to an AAO sensor-based method and kit for detecting a target material. The inventive method for a target material using an aptamer can detect even low-molecular-weight materials which were difficult to detect in the prior art, thereby enabling detection of disease-related metabolites, environmental pollutants and food toxins in solutions. In addition, the detection method of the present invention is a direct and simple method and is highly cost-effective, because it uses the aptamer which can be consistently reproduced and can be produced at low costs.Type: ApplicationFiled: February 16, 2010Publication date: February 16, 2012Inventor: So Youn Kim
-
Patent number: 8114978Abstract: Methods for genotyping polymorphisms using a locus specific primer that is complementary to a region near a selected polymorphism are described. Methods for synthesizing pools of locus specific primers that incorporate some degenerate positions are also disclosed. A plurality of different sequence capture probes are synthesized simultaneously using degenerate oligonucleotide synthesis. The sequence of the locus specific regions of the capture probes are related in that they have some bases that are identical in each sequence in the plurality of sequences and positions that vary from one locus specific region to another. The sequences are selected based on proximity to a polymorphism of interest and because they conform to a similar sequence pattern.Type: GrantFiled: December 2, 2008Date of Patent: February 14, 2012Assignee: Affymetrix, Inc.Inventors: Keith W. Jones, Michael H. Shapero, Stephen P. A. Fodor
-
Patent number: 8093025Abstract: The present invention relates to a combination of compounds for introducing nucleic acids and/or protein into animal cells, tissue, organs or organisms in vitro, extracorporal, or in vivo. This combination comprises preparations suitable for administration to an animal or human for medical purposes, comprising as one component a bacterial vector genetically manipulated to contain nucleic acid sequences comprising a transgene, and a second component for the subsequent transcription, possibly translation of the transgene by controlled induction of bacterial vector as it is present within the animal or human.Type: GrantFiled: September 2, 2005Date of Patent: January 10, 2012Assignee: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Holger Loessner, Anne Endmann, Sara Leschner, Siegfried Weiss
-
Publication number: 20110318316Abstract: Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID NO: 3; and a Requiem sequence shown as SEQ ID NO: 4.Type: ApplicationFiled: April 13, 2011Publication date: December 29, 2011Applicant: Agency for Science, Technology and ResearchInventors: Chee Furng WONG, Miranda Gek Sim Yap
-
Publication number: 20110318317Abstract: Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID NO: 3; and a Requiem sequence shown as SEQ ID NO: 4.Type: ApplicationFiled: April 13, 2011Publication date: December 29, 2011Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: CHEE FURNG WONG, MIRANDA GEK SIM YAP